Rita C. Peters

While the players may change, pharma’s patients-first focus should not.

Congress questions FDA on plans to catch up and move forward with facility inspections.

Bio/pharmaceutical manufacturers have made a good first step toward global vaccination through pledging doses at no- to low-profit rates.

As face masks start to come off, bio/pharma’s COVID-19 battle goes on.

Smart, accurate, science-based messaging is needed to advance bio/pharma science.

Bio/pharma works hard today to change the calendar to tomorrow.

A complicated vaccination rollout and mixed messages may derail the pandemic endgame.

Biopharma looks to deliver on COVID-19 vaccines and other promising therapies.

Essential bio/pharma employees show hard work and dedication can pay off for patients.

Demand for specific advanced laboratory skills drives creates a positive employment market.

Shutting down the COVID-19 pandemic requires a global, selfless effort.

After a difficult year, bio/pharma science delivers promising results.

Resolving drug shortages starts with identifying the source of the problem.

Misleading messages contribute to eroding trust in public health agencies.

Amid high expectations for a vaccine, bio/pharma readies capacity, weighs pressures.

Time sure flies, except when you are waiting for something to happen.

FDA Commissioner Hahn commits to a science-based review and approval process.

Achieving herd immunity will require testing, data, a vaccine, and public support.

Will moving at “warp speed” to develop a vaccine impact efficacy or safety?

As the coronavirus pandemic unfolds, Pharma must practice science over hype.

With some FDA inspections on hold, will the US drug supply maintain its quality standards?

Emergency action to protect patients and the drug supply may have long-term implications.

Can investing in early formulation studies drive a new therapy successfully across the commercialization finish line?

Bio/pharma researchers mobilize to diagnose and treat patients in pandemic threat.

The need for manufacturing speed inspires contract manufacturers to explore advanced processing technologies.

Achieving effective manufacturing processes and sufficient capacity remains a top priority across a diversified biologic drug pipeline.

The promise of new therapies is tempered by the need for affordability, safety, and ethics.

With a positive employment market, some bio/pharma professionals explore options for career advancement.

Warning letters tell the tale of missteps by drug companies and offer a path to compliance for quality teams that monitor these enforcement actions.

Nearly four decades after the first diagnosis, the fight to treat HIV/AIDs continues.